

Erica Franceschini, MD, PhD

## CURRICULUM VITAE

### CONTACT INFORMATION

Name: Erica Franceschini

Date of birth: 9<sup>th</sup> January 1984

Professional Address: Infectious Disease Clinic, Azienda Ospedaliero-Universitaria di Modena, Via del Pozzo 71, 41124 Modena, Italy

Professional phone number: +390594225317

E-mail address: efranceschini@unimore.it

### EDUCATION

- School-leaving examination at “Tassoni” Scientific Liceo in Modena, Italy, passed in July 2002 with full marks
- Graduated in Medicine and Surgery at the University of Modena and Reggio Emilia, Italy, with full marks and honors with a degree thesis entitled “Acute HIV infection: immunological impairment and prognostic role of PET” on the 16<sup>th</sup> of July 2008
- June 2014: Infectious Disease Specialist (Board Certified) at Modena and Reggio Emilia University Teaching Hospital, Italy
- In 2013 two months antibiotic stewardship activity at S.Orsola Hospital Infectious Disease School (Bologna, Italy), under Prof. P.L.Viale
- In 2014 three-month observership in the Transplant Infectious Diseases Program in Mount Sinai Hospital (New York City) under Prof.S.Huprikar
- November 2014-September 2018: PhD in “Clinical and Experimental Medicine (CEM)” at the University of Modena and Reggio Emilia. Degree thesis entitled “Immunological predictors of successful and safe anti-rejection therapy in HIV positive patients who underwent liver transplantation”

### LICENCE AND CERTIFICATIONS

- February 2009: license to practice medicine in Italy (Albo Medici Chirurghi di Modena n. 6302)

### EMPLOYMENT

- January 2015-January 2024: physician in the Infectious Diseases Clinic, Modena and Reggio Emilia University Teaching Hospital, Italy
- February 2024-present: Assistant Professor (Ricercatore t.d. art. 24 c. 3 lett. B) at: Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Università degli Studi di Modena e Reggio Emilia. Attending at the Infectious Diseases Clinic, Modena and Reggio Emilia University Teaching Hospital, Italy

## SCIENTIFIC RESEARCHES AS COLLABORATOR/SUB-INVESTIGATOR

- ISS-T002, “A phase II randomized, open label, immunogenicity and safety trial of the vaccine based on the recombinant biologically active HIV-1 TAT protein in anti-TAT negative HIV-1 infected HAART-treated adult subjects”
  - ISS-P002, “A phase I, open label, safety and immunogenicity vaccine trial based on the association of recombinant HIV-1 biologically active TAT and V2-deleted ENV proteins in HIV uninfected healthy adult volunteers”
  - Protocol VX-950HEP3002 (EAP Telaprevir), “Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis”
  - EuroSIDA Study
  - Rescuing Study, Combacte-Magnet-Rescuing Study
  - ReStore, “A phase 3, Multicenter, Randomized, Double-blind study of the efficacy and safety of rezafungin for injection versus intravenous caspofungin followed by optional oral fluconazole step-down in the treatment of subjects with candidemia and/or invasive candidiasis”
  - Eradicate, “A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including infective endocarditis”
  - Revisit, “A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-B-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTION”
- 
- MARIO, “A phase 3, multicenter, prospective, randomized, double-blind study of two treatment regimens for candidemia and/or invasive candidiasis: intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole”
  - OASIS, “A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species”

## MEMBERSHIP

-SIMIT

-SITA

-ESCMID (including ESGICH, ESGIE and EFISG subgroups)

Modena, 09-07-25

Enza Franceschi